KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Expenses (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Operating Expenses data on record, last reported at $46.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 13.9% year-over-year to $46.6 million; the TTM value through Dec 2025 reached $168.8 million, up 8.85%, while the annual FY2025 figure was $168.8 million, 8.85% up from the prior year.
  • Operating Expenses reached $46.6 million in Q4 2025 per RIGL's latest filing, up from $41.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $49.2 million in Q4 2022 and bottomed at $32.2 million in Q2 2023.
  • Average Operating Expenses over 5 years is $39.9 million, with a median of $40.7 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: increased 28.47% in 2021, then crashed 31.25% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $41.8 million in 2021, then increased by 17.62% to $49.2 million in 2022, then plummeted by 31.25% to $33.8 million in 2023, then increased by 21.03% to $40.9 million in 2024, then grew by 13.9% to $46.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $46.6 million in Q4 2025, $41.0 million in Q3 2025, and $40.6 million in Q2 2025.